{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T19:31:03Z","timestamp":1788982263124,"version":"build-2803163510"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T00:00:00Z","timestamp":1704758400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T00:00:00Z","timestamp":1704758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Seed Foundation of Tianjin Medical University Cancer Institute and Hospital"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Ovarian cancer is the most lethal malignancy among gynecologic cancers, and primary and secondary chemotherapy resistance is one of the important reasons for poor prognosis of ovarian cancer patients. However, the specifics of resistance to chemotherapy in ovarian cancer remain unclear. Herein, we find that the expression level of cellular retinoic acid binding protein 2 (CRABP2) is up-regulated in drug-resistant ovarian cancer tissues and cell lines, and the expression levels of CRABP2 in epithelial ovarian cancer tissues are closely related to tumor clinical stage and patients\u2019 prognosis, suggesting that CRABP2 plays an important role in the progression of ovarian cancer and the corresponding ability of tumor to chemotherapy. With the in-depth study, we demonstrates that CRABP2 is related to the high metabolic activity in drug-resistant cells, and all-trans retinoic acid exacerbates this activity. Further molecular mechanism exploration experiments show that CRABP2 not only up-regulates the expression level of HIF1\u03b1, but also increases the localization of HIF1\u03b1 in the nucleus. In drug-resistant ovarian cancer cells, knocking down HIF1\u03b1 can block the resistance of CRABP2 to chemotherapy drugs in ovarian cancer cells. Taken together, our findings suggest for the first time that CRABP2 affects chemotherapy resistance of ovarian cancer by regulating the expression of HIF1\u03b1. This study provides a possible molecular mechanism for drug resistance and a possible molecular target for clinical treatment of ovarian cancer.<\/jats:p>","DOI":"10.1038\/s41419-023-06398-4","type":"journal-article","created":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T14:02:17Z","timestamp":1704808937000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["CRABP2 affects chemotherapy resistance of ovarian cancer by regulating the expression of HIF1\u03b1"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8842-0645","authenticated-orcid":false,"given":"Xin","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaosong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuping","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,9]]},"reference":[{"key":"6398_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7\u201333.","journal-title":"CA Cancer J Clin"},{"key":"6398_CR2","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.3390\/cancers14092230","volume":"14","author":"J Huang","year":"2022","unstructured":"Huang J, Chan WC, Ngai CH, Lok V, Zhang L, Lucero-Prisno DE 3rd, et al. Worldwide Burden, Risk Factors, and Temporal Trends of Ovarian Cancer: A Global Study. Cancers. 2022;14:2230.","journal-title":"Cancers"},{"key":"6398_CR3","doi-asserted-by":"publisher","first-page":"6532","DOI":"10.3390\/ijms22126532","volume":"22","author":"S Morand","year":"2021","unstructured":"Morand S, Devanaboyina M, Staats H, Stanbery L, Nemunaitis J. Ovarian Cancer Immunotherapy and Personalized Medicine. Int J Mol Sci. 2021;22:6532.","journal-title":"Int J Mol Sci"},{"key":"6398_CR4","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1186\/s12905-022-02016-1","volume":"22","author":"KA Lawson-Michod","year":"2022","unstructured":"Lawson-Michod KA, Watt MH, Grieshober L, Green SE, Karabegovic L, Derzon S, et al. Pathways to ovarian cancer diagnosis: a qualitative study. BMC women\u2019s health. 2022;22:430.","journal-title":"BMC women\u2019s health"},{"key":"6398_CR5","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.biocel.2018.11.012","volume":"106","author":"Z Pieterse","year":"2019","unstructured":"Pieterse Z, Amaya-Padilla MA, Singomat T, Binju M, Madjid BD, Yu Y, et al. Ovarian cancer stem cells and their role in drug resistance. Int J Biochem cell Biol. 2019;106:117\u201326.","journal-title":"Int J Biochem cell Biol"},{"key":"6398_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-021-02136-y","volume":"21","author":"W Xie","year":"2021","unstructured":"Xie W, Sun H, Li X, Lin F, Wang Z, Wang X. Ovarian cancer: epigenetics, drug resistance, and progression. Cancer Cell Int. 2021;21:434.","journal-title":"Cancer Cell Int"},{"key":"6398_CR7","doi-asserted-by":"publisher","first-page":"6246","DOI":"10.3390\/cancers14246246","volume":"14","author":"KL Alatise","year":"2022","unstructured":"Alatise KL, Gardner S, Alexander-Bryant A. Mechanisms of Drug Resistance in Ovarian Cancer and Associated Gene Targets. Cancers. 2022;14:6246.","journal-title":"Cancers"},{"key":"6398_CR8","first-page":"186","volume":"37","author":"M Liu","year":"2022","unstructured":"Liu M, Zhang H, Li Y, Wang S. Noncoding RNAs Interplay in Ovarian Cancer Therapy and Drug Resistance. Cancer Biother Radiopharm. 2022;37:186\u201398.","journal-title":"Cancer Biother Radiopharm"},{"key":"6398_CR9","doi-asserted-by":"publisher","first-page":"1173863","DOI":"10.3389\/fonc.2023.1173863","volume":"13","author":"J Liu","year":"2023","unstructured":"Liu J, Ma J, Zhang J, Li C, Yu B, Choe HC, et al. Bibliometric and visualized analysis of drug resistance in ovarian cancer from 2013 to 2022. Front Oncol. 2023;13:1173863.","journal-title":"Front Oncol"},{"key":"6398_CR10","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.cbpb.2013.02.006","volume":"165","author":"MB Parmar","year":"2013","unstructured":"Parmar MB, Lee JJ, Wright JM. Duplicated crabp1 and crabp2 genes in medaka (Oryzias latipes): gene structure, phylogenetic relationship and tissue-specific distribution of transcripts. Comp Biochem Physiol Part B, Biochem Mol Biol. 2013;165:10\u20138.","journal-title":"Comp Biochem Physiol Part B, Biochem Mol Biol"},{"key":"6398_CR11","doi-asserted-by":"publisher","first-page":"4183","DOI":"10.1021\/acs.biochem.9b00672","volume":"58","author":"C Lixa","year":"2019","unstructured":"Lixa C, Clarkson MW, Iqbal A, Moon TM, Almeida FCL, Peti W, et al. Retinoic Acid Binding Leads to CRABP2 Rigidification and Dimerization. Biochemistry. 2019;58:4183\u201394.","journal-title":"Biochemistry"},{"key":"6398_CR12","doi-asserted-by":"publisher","first-page":"42749","DOI":"10.1074\/jbc.M111.293464","volume":"286","author":"A Majumdar","year":"2011","unstructured":"Majumdar A, Petrescu AD, Xiong Y, Noy N. Nuclear translocation of cellular retinoic acid-binding protein II is regulated by retinoic acid-controlled SUMOylation. J Biol Chem. 2011;286:42749\u201357.","journal-title":"J Biol Chem"},{"key":"6398_CR13","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1128\/MCB.00281-14","volume":"34","author":"AC Vreeland","year":"2014","unstructured":"Vreeland AC, Yu S, Levi L, de Barros Rossetto D, Noy N. Transcript stabilization by the RNA-binding protein HuR is regulated by cellular retinoic acid-binding protein 2. Mol Cell Biol. 2014;34:2135\u201346.","journal-title":"Mol Cell Biol"},{"key":"6398_CR14","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.ygyno.2022.09.020","volume":"167","author":"D Egan","year":"2022","unstructured":"Egan D, Moran B, Wilkinson M, Pinyol M, Guerra E, Gatius S, et al. CRABP2 - A novel biomarker for high-risk endometrial cancer. Gynecol Oncol. 2022;167:314\u201322.","journal-title":"Gynecol Oncol"},{"key":"6398_CR15","doi-asserted-by":"publisher","first-page":"110372","DOI":"10.1016\/j.cbi.2023.110372","volume":"373","author":"S Zeng","year":"2023","unstructured":"Zeng S, Xu Z, Liang Q, Thakur A, Liu Y, Zhou S, et al. The prognostic gene CRABP2 affects drug sensitivity by regulating docetaxel-induced apoptosis in breast invasive carcinoma: A pan-cancer analysis. Chem-Biol Interact. 2023;373:110372.","journal-title":"Chem-Biol Interact"},{"key":"6398_CR16","first-page":"3098327","volume":"2020","author":"Q Chen","year":"2020","unstructured":"Chen Q, Tan L, Jin Z, Liu Y, Zhang Z. Downregulation of CRABP2 Inhibit the Tumorigenesis of Hepatocellular Carcinoma In Vivo and In Vitro. Biomed Res Int. 2020;2020:3098327.","journal-title":"Biomed Res Int"},{"key":"6398_CR17","doi-asserted-by":"publisher","first-page":"9111681","DOI":"10.1155\/2022\/9111681","volume":"2022","author":"Q Yi","year":"2022","unstructured":"Yi Q, Miao Y, Kong Y, Xu Y, Zhou J, Dong Q, et al. MiR-579 Inhibits Lung Adenocarcinoma Cell Proliferation and Metastasis via Binding to CRABP2. Comput Math Methods Med. 2022;2022:9111681.","journal-title":"Comput Math Methods Med"},{"key":"6398_CR18","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1186\/s13046-019-1345-2","volume":"38","author":"X Feng","year":"2019","unstructured":"Feng X, Zhang M, Wang B, Zhou C, Mu Y, Li J, et al. CRABP2 regulates invasion and metastasis of breast cancer through hippo pathway dependent on ER status. J Exp Clin cancer Res : CR. 2019;38:361.","journal-title":"J Exp Clin cancer Res : CR"},{"key":"6398_CR19","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1093\/molehr\/gam040","volume":"13","author":"M Zaitseva","year":"2007","unstructured":"Zaitseva M, Vollenhoven BJ, Rogers PA. Retinoic acid pathway genes show significantly altered expression in uterine fibroids when compared with normal myometrium. Mol Hum Reprod. 2007;13:577\u201385.","journal-title":"Mol Hum Reprod"},{"key":"6398_CR20","doi-asserted-by":"publisher","first-page":"e178","DOI":"10.3346\/jkms.2018.33.e178","volume":"33","author":"DJ Kim","year":"2018","unstructured":"Kim DJ, Kim WJ, Lim M, Hong Y, Lee SJ, Hong SH, et al. Plasma CRABP2 as a Novel Biomarker in Patients with Non-Small Cell Lung Cancer. J Korean Med Sci. 2018;33:e178.","journal-title":"J Korean Med Sci"},{"key":"6398_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-37443-4","volume":"9","author":"JI Wu","year":"2019","unstructured":"Wu JI, Lin YP, Tseng CW, Chen HJ, Wang LH. Crabp2 Promotes Metastasis of Lung Cancer Cells via HuR and Integrin beta1\/FAK\/ERK Signaling. Sci Rep. 2019;9:845.","journal-title":"Sci Rep"},{"key":"6398_CR22","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1593\/neo.91110","volume":"11","author":"MF Calmon","year":"2009","unstructured":"Calmon MF, Rodrigues RV, Kaneto CM, Moura RP, Silva SD, Mota LD, et al. Epigenetic silencing of CRABP2 and MX1 in head and neck tumors. Neoplasia. 2009;11:1329\u201339.","journal-title":"Neoplasia"},{"key":"6398_CR23","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s12672-022-00492-3","volume":"13","author":"N Li","year":"2022","unstructured":"Li N, Lin G, Zhang Y, Zhang Q, Zhang H. Exosome-related protein CRABP2 is upregulated in ovarian carcinoma and enhances cell proliferation. Discov Oncol. 2022;13:33.","journal-title":"Discov Oncol"},{"key":"6398_CR24","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1002\/tox.23542","volume":"37","author":"T Xie","year":"2022","unstructured":"Xie T, Tan M, Gao Y, Yang H. CRABP2 accelerates epithelial mesenchymal transition in serous ovarian cancer cells by promoting TRIM16 methylation via upregulating EZH2 expression. Environ Toxicol. 2022;37:1957\u201367.","journal-title":"Environ Toxicol"},{"key":"6398_CR25","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1042\/BCJ20170712","volume":"475","author":"Y Hekmatshoar","year":"2018","unstructured":"Hekmatshoar Y, Nakhle J, Galloni M, Vignais ML. The role of metabolism and tunneling nanotube-mediated intercellular mitochondria exchange in cancer drug resistance. Biochem J. 2018;475:2305\u201328.","journal-title":"Biochem J"},{"key":"6398_CR26","doi-asserted-by":"publisher","first-page":"807636","DOI":"10.3389\/fonc.2021.807636","volume":"11","author":"M Bataller","year":"2021","unstructured":"Bataller M, S\u00e1nchez-Garc\u00eda A, Garcia-Mayea Y, Mir C, Rodriguez I, LLeonart ME. The Role of Sphingolipids Metabolism in Cancer Drug Resistance. Front Oncol. 2021;11:807636.","journal-title":"Front Oncol"},{"key":"6398_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-022-00991-w","volume":"8","author":"Y Li","year":"2022","unstructured":"Li Y, Zeng P, Xiao J, Huang P, Liu P. Modulation of energy metabolism to overcome drug resistance in chronic myeloid leukemia cells through induction of autophagy. Cell death Discov. 2022;8:212.","journal-title":"Cell death Discov"},{"key":"6398_CR28","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1172\/JCI127201","volume":"129","author":"Y Cao","year":"2019","unstructured":"Cao Y. Adipocyte and lipid metabolism in cancer drug resistance. J Clin Invest. 2019;129:3006\u201317.","journal-title":"J Clin Invest"},{"key":"6398_CR29","doi-asserted-by":"publisher","first-page":"140","DOI":"10.3390\/cells11010140","volume":"11","author":"HC Yoo","year":"2022","unstructured":"Yoo HC, Han JM. Amino Acid Metabolism in Cancer Drug Resistance. Cells. 2022;11:140.","journal-title":"Cells"},{"key":"6398_CR30","first-page":"9950","volume":"13","author":"C Nantasupha","year":"2021","unstructured":"Nantasupha C, Thonusin C, Charoenkwan K, Chattipakorn S, Chattipakorn N. Metabolic reprogramming in epithelial ovarian cancer. Am J Transl Res. 2021;13:9950\u201373.","journal-title":"Am J Transl Res"},{"key":"6398_CR31","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1038\/cdd.2016.39","volume":"23","author":"DS Matassa","year":"2016","unstructured":"Matassa DS, Amoroso MR, Lu H, Avolio R, Arzeni D, Procaccini C, et al. Oxidative metabolism drives inflammation-induced platinum resistance in human ovarian cancer. Cell Death Differ. 2016;23:1542\u201354.","journal-title":"Cell Death Differ"},{"key":"6398_CR32","first-page":"1055","volume":"53","author":"Y Xu","year":"2018","unstructured":"Xu Y, Gao W, Zhang Y, Wu S, Liu Y, Deng X, et al. ABT737 reverses cisplatin resistance by targeting glucose metabolism of human ovarian cancer cells. Int J Oncol. 2018;53:1055\u201368.","journal-title":"Int J Oncol"},{"key":"6398_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-09206-0","volume":"7","author":"S Dar","year":"2017","unstructured":"Dar S, Chhina J, Mert I, Chitale D, Buekers T, Kaur H, et al. Bioenergetic Adaptations in Chemoresistant Ovarian Cancer Cells. Sci Rep. 2017;7:8760.","journal-title":"Sci Rep"},{"key":"6398_CR34","doi-asserted-by":"publisher","first-page":"5703","DOI":"10.3390\/ijms22115703","volume":"22","author":"V Infantino","year":"2021","unstructured":"Infantino V, Santarsiero A, Convertini P, Todisco S, Iacobazzi V. Cancer Cell Metabolism in Hypoxia: Role of HIF-1 as Key Regulator and Therapeutic Target. Int J Mol Sci. 2021;22:5703.","journal-title":"Int J Mol Sci"},{"key":"6398_CR35","doi-asserted-by":"publisher","first-page":"849040","DOI":"10.3389\/fgene.2022.849040","volume":"13","author":"A Sharma","year":"2022","unstructured":"Sharma A, Sinha S, Shrivastava N. Therapeutic Targeting Hypoxia-Inducible Factor (HIF-1) in Cancer: Cutting Gordian Knot of Cancer Cell Metabolism. Front Genet. 2022;13:849040.","journal-title":"Front Genet"},{"key":"6398_CR36","doi-asserted-by":"publisher","first-page":"225","DOI":"10.7150\/ijbs.75459","volume":"19","author":"H Song","year":"2023","unstructured":"Song H, Qiu Z, Wang Y, Xi C, Zhang G, Sun Z, et al. HIF-1alpha\/YAP Signaling Rewrites Glucose\/Iodine Metabolism Program to Promote Papillary Thyroid Cancer Progression. Int J Biol Sci. 2023;19:225\u201341.","journal-title":"Int J Biol Sci"},{"key":"6398_CR37","doi-asserted-by":"publisher","first-page":"eade5111","DOI":"10.1126\/sciadv.ade5111","volume":"9","author":"JW Cheu","year":"2023","unstructured":"Cheu JW, Chiu DK, Kwan KK, Yang C, Yuen VW, Goh CC, et al. Hypoxia-inducible factor orchestrates adenosine metabolism to promote liver cancer development. Sci Adv. 2023;9:eade5111.","journal-title":"Sci Adv"},{"key":"6398_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01965-8","volume":"8","author":"W Du","year":"2017","unstructured":"Du W, Zhang L, Brett-Morris A, Aguila B, Kerner J, Hoppel CL, et al. HIF drives lipid deposition and cancer in ccRCC via repression of fatty acid metabolism. Nat Commun. 2017;8:1769.","journal-title":"Nat Commun"},{"key":"6398_CR39","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1158\/1541-7786.MCR-18-1343","volume":"17","author":"MJ VandeKopple","year":"2019","unstructured":"VandeKopple MJ, Wu J, Auer EN, Giaccia AJ, Denko NC, Papandreou I. HILPDA Regulates Lipid Metabolism, Lipid Droplet Abundance, and Response to Microenvironmental Stress in Solid Tumors. Mol Cancer Res. 2019;17:2089\u2013101.","journal-title":"Mol Cancer Res"},{"key":"6398_CR40","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s00018-020-03483-1","volume":"78","author":"B Zhang","year":"2021","unstructured":"Zhang B, Chen Y, Shi X, Zhou M, Bao L, Hatanpaa KJ, et al. Regulation of branched-chain amino acid metabolism by hypoxia-inducible factor in glioblastoma. Cell Mol Life Sci. 2021;78:195\u2013206.","journal-title":"Cell Mol Life Sci"},{"key":"6398_CR41","doi-asserted-by":"publisher","first-page":"784777","DOI":"10.3389\/fonc.2021.784777","volume":"11","author":"T Tian","year":"2021","unstructured":"Tian T, Han J, Huang J, Li S, Pang H. Hypoxia-Induced Intracellular and Extracellular Heat Shock Protein gp96 Increases Paclitaxel-Resistance and Facilitates Immune Evasion in Breast Cancer. Front Oncol. 2021;11:784777.","journal-title":"Front Oncol"},{"key":"6398_CR42","doi-asserted-by":"publisher","first-page":"2876","DOI":"10.21037\/tcr-22-1812","volume":"11","author":"H Li","year":"2022","unstructured":"Li H, Wang J, Jin Y, Lin J, Gong L, Xu Y. Hypoxia upregulates the expression of lncRNA H19 in non-small cell lung cancer cells and induces drug resistance. Transl Cancer Res. 2022;11:2876\u201386.","journal-title":"Transl Cancer Res"},{"key":"6398_CR43","doi-asserted-by":"publisher","first-page":"6054","DOI":"10.3390\/cancers14246054","volume":"14","author":"BP Bui","year":"2022","unstructured":"Bui BP, Nguyen PL, Lee K, Cho J. Hypoxia-Inducible Factor-1: A Novel Therapeutic Target for the Management of Cancer, Drug Resistance, and Cancer-Related Pain. Cancers. 2022;14:6054.","journal-title":"Cancers"},{"key":"6398_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-02768-4","volume":"11","author":"K Xu","year":"2020","unstructured":"Xu K, He Z, Chen M, Wang N, Zhang D, Yang L, et al. HIF-1alpha regulates cellular metabolism, and Imatinib resistance by targeting phosphogluconate dehydrogenase in gastrointestinal stromal tumors. Cell Death Dis. 2020;11:586.","journal-title":"Cell Death Dis"},{"key":"6398_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05299-2","volume":"13","author":"X Tang","year":"2022","unstructured":"Tang X, Liang Y, Sun G, He Q, Hou Z, Jiang X, et al. Upregulation of CRABP2 by TET1-mediated DNA hydroxymethylation attenuates mitochondrial apoptosis and promotes oxaliplatin resistance in gastric cancer. Cell Death Dis. 2022;13:848.","journal-title":"Cell Death Dis"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-06398-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-06398-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-06398-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T14:10:41Z","timestamp":1704809441000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-06398-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,9]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["6398"],"URL":"https:\/\/doi.org\/10.1038\/s41419-023-06398-4","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,9]]},"assertion":[{"value":"28 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki, and approved by the Ethics Committee of Tianjin Medical University Cancer Institute and Hospital (bc2021291 and 22 December 2021). The animal experiment protocol and ethical requirements were approved by the Experimental Animal Ethics Committee of Tianjin Medical University Cancer Institute and Hospital (LWFB-AE-20210057).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all subjects involved in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent Statement"}}],"article-number":"21"}}